Pacira BioSciences reported a 2% year-over-year revenue decline in Q3 2026, but saw growth in its key products, EXPAREL and ZILRETTA. Earnings were positively impacted by a contingent consideration gain and a divestiture gain from the iovera° business sale, providing a mixed financial picture for investors.
Pacira BioSciences reported Q3 2026 financial results, showing a 2% year-over-year revenue decline to $176.65 million. This decline is a negative signal, but was partially offset by 2% growth in EXPAREL sales and 3% growth in ZILRETTA sales, indicating underlying strength in core products. Earnings were significantly bolstered by a $14.4 million contingent consideration gain and a $6.6 million divestiture gain from the sale of its iovera° business to Zimmer, which completed in July. For traders, the short-term implications are mixed: revenue is down, but core product growth and one-time gains provide a cushion. The long-term outlook will depend on continued product growth and pipeline advancements like the ASCEND study for PCRX-201, with results expected by year-end. The key opportunity lies in the potential positive data from the PCRX-201 study, which could re-rate the stock despite the current revenue dip.